Oculis rakes in Series A funds
Oculis, a developer of ophthalmic drugs, has raised an undisclosed amount of Series A funding. Brunnur Ventures and Silfurberg were the lead investors. In conjunction with the funding, Árni Blöndal of Brunnur Ventures and Stefan Jökull Sveinsson, former global R&D head at Actavis, have been added to the Oculis board.
16 August 2016•1 min read
